Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice
Raife Dilek Turan
(Acibadem Labcell Cellular Therapy Laboratory)
Cihan Tastan
(Acibadem Labcell Cellular Therapy Laboratory)
Derya Dilek Kancagi
(Acibadem Labcell Cellular Therapy Laboratory)
Bulut Yurtsever
(Acibadem Labcell Cellular Therapy Laboratory)
Gozde Sir Karakus
(Acibadem Labcell Cellular Therapy Laboratory)
Samed Ozer
(Animal Application and Research Center, Acibadem Mehmet Ali Aydinlar University)
Selen Abanuz
(Acibadem Labcell Cellular Therapy Laboratory)
Didem Cakirsoy
(Acibadem Labcell Cellular Therapy Laboratory)
Gamze Tumentemur
(Vocational School of Health Services, Acibadem Mehmet Ali Aydinlar University)
Sevda Demir
(Genetics and Bioengineering Department, Yeditepe University)
Utku Seyis
(Acibadem Labcell Cellular Therapy Laboratory)
Recai Kuzay
(Acibadem Labcell Cellular Therapy Laboratory)
Muhammer Elek
(Acibadem Labcell Cellular Therapy Laboratory)
Miyase Ezgi Kocaoglu
(Acibadem Labcell Cellular Therapy Laboratory)
Gurcan Ertop
(Vocational School of Health Services, Acibadem Mehmet Ali Aydinlar University)
Serap Arbak
(Histology and Embryology Department, Acibadem Mehmet Ali Aydinlar University)
Merve Acikel Elmas
(Histology and Embryology Department, Acibadem Mehmet Ali Aydinlar University)
Cansu Hemsinlioglu
(Acibadem Labcell Cellular Therapy Laboratory)
Ozden Hatirnaz Ng
(Medical Biology Department, Acibadem Mehmet Ali Aydinlar University)
Sezer Akyoney
(Medical Biology Department, Acibadem Mehmet Ali Aydinlar University)
Ilayda Sahin
(Medical Biotechnology Department, Acibadem Mehmet Ali Aydinlar University)
Cavit Kerem Kayhan
(Pathology Laboratory, Acibadem Maslak Hospital)
Fatma Tokat
(Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University)
Gurler Akpinar
(Department of Medical Biology, Medical School of Kocaeli University)
Murat Kasap
(Department of Medical Biology, Medical School of Kocaeli University)
Ayse Sesin Kocagoz
(Infectious Disease Unit, Acibadem Altunizade Hospital)
Ugur Ozbek
(Medical Genetics Department, Acibadem Mehmet Ali Aydinlar University)
Dilek Telci
(Genetics and Bioengineering Department, Yeditepe University)
Fikrettin Sahin
(Genetics and Bioengineering Department, Yeditepe University)
Koray Yalcin
(Acibadem Labcell Cellular Therapy Laboratory)
Siret Ratip
(Hematology Department, School of Medicine, Acibadem Mehmet Ali Aydinlar University)
Umit Ince
(Department of Pathology, School of Medicine, Acibadem Mehmet Ali Aydinlar University)
Ercument Ovali
(Acibadem Labcell Cellular Therapy Laboratory)
Abstract The SARS-CoV-2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A and smallpox proved to be reliable approaches for immunization for prolonged periods. In this study, a gamma-irradiated inactivated virus vaccine does not require an extra purification process, unlike the chemically inactivated vaccines. Hence, the novelty of our vaccine candidate (OZG-38.61.3) is that it is a non-adjuvant added, gamma-irradiated, and intradermally applied inactive viral vaccine. Efficiency and safety dose (either 1013 or 1014 viral RNA copy per dose) of OZG-38.61.3 was initially determined in BALB/c mice. This was followed by testing the immunogenicity and protective efficacy of the vaccine. Human ACE2-encoding transgenic mice were immunized and then infected with the SARS-CoV-2 virus for the challenge test. This study shows that vaccinated mice have lowered SARS-CoV-2 viral RNA copy numbers both in oropharyngeal specimens and in the histological analysis of the lung tissues along with humoral and cellular immune responses, including the neutralizing antibodies similar to those shown in BALB/c mice without substantial toxicity. Subsequently, plans are being made for the commencement of Phase 1 clinical trial of the OZG-38.61.3 vaccine for the COVID-19 pandemic.